Tagged with development

R&D Professor Dr. Robert Riener speaks about the much anticipated Cybathlon event and its importance to technology transfer, the Swiss education system’s ability to attract international talent, and his goals for the future. You have been leading the Department of Health Sciences and Technology at ETH Zurich since February 2016. Could…

Pharma Agnès Ducrot and Miklos Maróthy of CCI France Hongrie discuss their advocacy efforts in Hungary and the history of French investment in the country. They also discuss the challenges and opportunities facing companies currently operating in the country. Can you give our readers an overview of the Chamber’s activities here in…

Pharma Riccardo Palmisano, CEO of MolMed, discusses the latest developments for their late-stage clinical development products, and comments on the recent approval of Strimvelis, a gene therapy developed by GSK and MolMed. Can you please give our readers a brief rundown of the history of MolMed since its foundation in 1996?…

Pharma Finding success in the shadows of Big Pharma and large research facilities, CleveXel serves as a bridge in the industry, specializing on selecting promising molecules for investment, and developing them for the CNS market, and especially Parkinson disease. Christian Bloy shares his entrepreneurial spirit and the vision for CleveXel, a…

Pharma Puerto Rico is starting to move towards greater R&D activity. World class research centers in cardiovascular, oncology, and soon molecular science are putting the territory on the global map for pharmaceutical research. But Puerto Rico is starting to move beyond manufacturing and towards greater R&D activity. Puerto Rico’s Cardiovascular and…

Pharma Fabrizio Greco, General Manager at AbbVie Italy, discusses the successful launch of the company’s new Hepatitis C treatment, how AbbVie is seeking to position itself as a partner to the authorities, and where the company’s next generation of growth drivers will be found. To start off, we are approaching the…

Pharma Lyon provides companies with a flamboyant and collaborative environment to develop. Bruno Masurel, Head of the International Division of the local Chamber of Commerce talks about the advantages the region offers and the services the institution has to help companies go international. Could you please explain the reasons behind the…

Pharma The CEO of Onxeo, recently formed through the merger of the French BioAlliance Pharma and the Danish Topotarget, discusses its strategic turning decision to focus on orphan oncology, its promising pipeline of innovative products, her “positively opportunistic” attitude towards partnerships and international expansion, and the company’s overall strategy for differentiating…

Pharma Manfred Rüdiger (MR), Robbert Van Heekeren (RVH) and Jeroen Rovers (JR), respectively CEO, CFO and CMO of Kiadis Pharma, a Dutch biopharmaceutical company focused on cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders, discuss how the company’s recent IPO will allow them to move forward…

Pharma Mr. Finn Søndergaard, CEO of Intsel Chimos, an independent French laboratory with a long history of expertise in the import of medicines for patients in a therapeutic impasse, highlights Intsel Chimos’ emphasis on innovation and R&D and discusses the promising orphan drug the company is in the process of developing. He…

Pharma Mr. Michel Finance, CEO of Theradiag, a leading French player in in vitro diagnostics and the novel field of theranostics (a combination of treatment and diagnosis), discusses the major restructuring at Theradiag he oversaw, the crucial role that diagnostics play in the provision of efficient as well as cost-effective healthcare…

Pharma Antimicrobial resistance is classified by the WHO as one of the top threats to humanity. The Business Unit Director for Europe and America of DSM Sinochem Pharmaceuticals, a global leader in environmentally friendly anti-infective molecules, explains the risks related to antimicrobial resistance, the role of the pharmaceutical industry and how…